已收录 268920 条政策
 政策提纲
  • 暂无提纲
Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant
[摘要] The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 
[关键词] allogeneic;cellular response;COVID-19;hematological;humoral response;SARS-CoV-2 mRNA;vaccine [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文